Compound class:
Synthetic organic
Comment: S4-1 is reported as a small molecule inhibitor of the PD-1/PD-L1 inhibitory immune checkpoint [1] that is exploited for cancer immunotherapy. It promotes dimerisation and internalisation of PD-L1 which reduces the opportunity of signaling via interaction with PD-1. As predicted, S4-1-induced PD-L1/PD-1 pathway blockade promotes T cell activation and reverses the immune inhibitory tumour microenvironment. In vivo, it has demonstrated anti-tumour effects in lung and colorectal cancer models (following intraperitoneal administration). Such small molecules are envisaged as alternatives to the existing anti-PD-L1 and anti-PD-1 monoclonal antibody therapeutics.
|
|
Selectivity at ligand targets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|